Boehringer Ingelheim Pharmaceuticals announced that the FDA has approved Viramune XR (nevirapine) extended-release tablets, a one-pill, once-daily (400mg) formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The approval of Viramune XR was based on data from the Phase 3 VERxVE study, which demonstrated that Viramune XR achieved a virologic response non-inferior to twice-daily immediate-release Viramune (200mg) through 48 weeks, both used in combination with Truvada, in treatment-naive HIV-1 infected adult patients.
Viramune XR is an NNRTI antiretroviral drug indicated for combination treatment of HIV-1 infection in adults. It is supplied as a tablet formulation.
For more information call (800) 548-6257 or visit www.viramunexr.com.